{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:11:57Z","timestamp":1787026317474,"version":"build-2736575974"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID\/PASC. The alveolar tissue and adjacent capillaries show inflammatory and procoagulatory activation with cell necrosis, thrombi, and massive fibrinoid deposits, namely, unsolvable microthrombi, which results in an obstructed gas exchange. Heparin-induced extracorporeal LDL\/fibrinogen precipitation (H.E.L.P.) apheresis solves these problems by helping the entire macro- and microcirculation extracorporeally. It uses unfractionated heparin, which binds the spike protein and thereby should remove the virus (debris). It dissolves the forming microthrombi without bleeding risk. It removes large amounts of fibrinogen (coagulation protein), which immediately improves the oxygen supply in the capillaries. In addition, it removes the precursors of both the procoagulatory and the fibrinolytic cascade, thus de-escalating the entire hemostaseological system. It increases myocardial, cerebral, and pulmonary blood flow rates, and coronary flow reserve, facilitating oxygen exchange in the capillaries, without bleeding risks. Another factor in COVID is the \u201ccytokine storm\u201d harming microcirculation in the lungs and other organs. Intervention by H.E.L.P. apheresis could prevent uncontrollable coagulation and inflammatory activity by removing cytokines such as interleukin (IL)-6, IL-8, and TNF-\u03b1, and reduces C-reactive protein, and eliminating endo- and ecto-toxins, without touching protective IgM\/IgG antibodies, leukocyte, or platelet function. The therapy can be used safely in combination with antiviral drugs, antibiotics, anticoagulants, or antihypertensive drugs. Long-term clinical experience with H.E.L.P. apheresis shows it cannot inflict harm upon patients with COVID-19.<\/jats:p>","DOI":"10.3389\/fcvm.2022.1007636","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T01:27:35Z","timestamp":1665451655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The potential of heparin-induced extracorporeal LDL\/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19"],"prefix":"10.3389","volume":"9","author":[{"given":"Beate Roxane","family":"Jaeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley Emma","family":"Arron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiltrud M.","family":"Kalka-Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7326\/L20-0895","article-title":"Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19","volume":"172","author":"Zhang","year":"2020","journal-title":"Ann Intern Med"},{"key":"B3","author":"Epidemiologisches","year":"2020","journal-title":"Schwereeinsch\u00e4tzung von COVID-19 mit Vergleichsdaten zu Pneumonien aus dem Krankenhaussentinel f\u00fcr schwere akute Atemwegserkrankungen am RKI (ICOSARI)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa2004500","article-title":"Covid-19 in critically ill patients in the seattle region\u2014case series","volume":"382","author":"Bhatraju","year":"2020","journal-title":"NEJM."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endothelitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature."},{"key":"B7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamacardio.2020.1096","article-title":"Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Inciardi","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamacardio.2020.0934","article-title":"An acute respiratory infection runs into the most common noncommunicable epidemic-COVID-19 and cardiovascular diseases","volume":"5","author":"Yang","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000515104","article-title":"Systematic review of microthrombi in COVID-19 autopsies","volume":"144","author":"Parra-Medina","year":"2021","journal-title":"Acta Haematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.3390\/ijms23095125","article-title":"Angiotensin II promotes SARS-CoV-2 infection via upregulation of ACE2 in human bronchial cells","volume":"23","author":"Caputo","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2174\/156652406778018707","article-title":"Links between inflammation and thrombogenicity in atherosclerosis","volume":"6","author":"Viles-Gonzalez","year":"2006","journal-title":"Curr Mol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.atherosclerosis.2010.03.019","article-title":"Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis","volume":"212","author":"Morel","year":"2010","journal-title":"Atherosclerosis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2021.04.003","article-title":"Molecular mapping of platelet hyperreactivity in diabetes: the stress proteins complex HSPA8\/Hsp90\/CSK2\u03b1 and platelet aggregation in diabetic and normal platelets","volume":"235","author":"Chiva-Blanch","year":"2021","journal-title":"Transl Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Infect."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.29.971093","article-title":"The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor binding domain undergoes conformational change upon heparin binding","author":"Mycroft-West","year":"2020","journal-title":"BioRxiv"},{"key":"B20","first-page":"2826","article-title":"Extracorporeal membrane oxygenation improves survival in a novel 24-hour pig model of severe acute respiratory distress syndrome","volume":"8","author":"Araos","year":"2016","journal-title":"Am J Transl Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s00134-016-4507-0","article-title":"Associations between ventilator settings during extracorporeal membrane oxygenation for refractory hypoxemia and outcome in patients with acute respiratory distress syndrome: a pooled individual patient data analysis","volume":"42","author":"Neto","year":"2016","journal-title":"Intensive Care Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13054-015-0996-4","article-title":"Bench-to-bedside review: the effects of hyperoxia during critical illness","volume":"19","author":"Helmerhorst","year":"2015","journal-title":"Crit Care."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1097\/CCM.0000000000000998","article-title":"Association between arterial hyperoxia and outcome in subsets of critical illness: a systematic review, meta-analysis, and meta-regression of cohort studies","volume":"43","author":"Helmerhorst","year":"2015","journal-title":"Crit Care Med."},{"key":"B24","first-page":"104","article-title":"Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application","volume":"32","author":"Eisenhauer","year":"1986","journal-title":"Trans Am Soc Artif Organs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jca.2920040207","article-title":"Removal of low-density lipoproteins (LDL) and fibrinogen by precipitation with heparin at low pH: clinical application and experience","volume":"4","author":"Seidel","year":"1988","journal-title":"J Clin Apheresis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1365-2362.1991.tb01384.x","article-title":"The HELP-LDL-Apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I evaluation of safety and cholesterol-lowering effects during the first 12 months","volume":"21","author":"Seidel","year":"1991","journal-title":"Eur J Clin Inv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2362.1994.tb01068.x","article-title":"The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the Course of Coronary Heart Disease","volume":"24","author":"Schuff-Werner","year":"1994","journal-title":"Eur J Clin Invest."},{"key":"B28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/BF01959530","article-title":"Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia","volume":"149","author":"Thiery","year":"1990","journal-title":"Eur J Pediatr"},{"key":"B29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1067\/mpd.2002.124384","article-title":"Long-term prevention of premature coronary atherosclerosis in homozygous familial hypercholesterolemia","volume":"141","author":"Jaeger","year":"2002","journal-title":"J Pediatrics"},{"key":"B30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00108-002-0832-1","article-title":"Coronary heart disease in childhood in familial hypercholesteremia. Maximum therapy with LDL apheresis","volume":"44","author":"Mellwig","year":"2003","journal-title":"Internist"},{"key":"B31","first-page":"28","article-title":"Clinical Long-Term Results of H.E.L.P.-Apheresis. Z Kardiol","volume":"92","author":"Schuff-Werner","year":"2003"},{"key":"B32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.healun.2005.05.009","article-title":"Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long-term heart transplant survivors using positron emission tomography","volume":"24","author":"Jaeger","year":"2005","journal-title":"J Heart Lung Transplant."},{"key":"B34","first-page":"290","article-title":"Regression of transplant coronary artery disease during low-density lipoprotein apheresis","volume":"16","author":"Park","year":"1997","journal-title":"JHLT."},{"key":"B35","first-page":"154","article-title":"Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation","volume":"96","author":"Jaeger","year":"1997","journal-title":"Circulation"},{"key":"B36","first-page":"331","article-title":"A combined treatment of statins and HELP apheresis for treatment of cardiac allograft vasculopathy","volume":"141","author":"Jaeger","year":"2002","journal-title":"Atherosclerosis Suppl."},{"key":"B37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1600-6143.2010.03401.x","article-title":"Early Prediction of cardiac allograft vasculopathy and heart transplant failure","volume":"11","author":"Labarrere","year":"2011","journal-title":"Am J Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e113260","DOI":"10.1371\/journal.pone.0113260","article-title":"Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients","volume":"9","author":"Labarrere","year":"2014","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2741\/e790","article-title":"Cardiac allograft vasculopathy: microvascular arteriolar capillaries (Capioles) and survival","volume":"9","author":"Labarrere","year":"2017","journal-title":"Front Biosc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1055\/s-0036-1584167","article-title":"Postoperative heparin-mediated extracorporeal low-density lipoprotein fibrinogen precipitation aphaeresis prevents early graft occlusion after coronary artery bypass grafting","volume":"2","author":"Oberhoffer","year":"2016","journal-title":"Surg J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.transci.2006.05.010","article-title":"Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia","volume":"35","author":"Wang","year":"2006","journal-title":"Transfus Apheres Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.atherosclerosissup.2019.08.028","article-title":"Apheresis as emerging treatment option in severe early onset preeclampsia","volume":"40","author":"Contini","year":"2019","journal-title":"Atheroscler Suppl."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/01.STR.24.10.1447","article-title":"Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen","volume":"24","author":"Walzl","year":"1993","journal-title":"Stroke"},{"key":"B44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000217153","article-title":"Increased cerebral perfusion following reduction of fibrinogen and lipid fractions","volume":"25","author":"Walzl","year":"1995","journal-title":"Haemostasis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1526-0968.2003.00072.x","article-title":"The HELP System for the treatment of atherothrombotic disorders: a review","volume":"7","author":"Jaeger","year":"2003","journal-title":"Therap Apheres Dialy"},{"key":"B46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1046\/j.1526-0968.2002.00427.x","article-title":"Case reports on emergency treatment of cardiovascular syndromes through heparin-mediated low-density lipoprotein\/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage","volume":"6","author":"Jaeger","year":"2002","journal-title":"Therap Apheres."},{"key":"B47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.atherosclerosissup.2015.02.019","article-title":"The impact of lipoprotein apheresis in patients with refractory angina and raised Lipoprotein(a): objectives and methods of a randomised controlled trial","volume":"18","author":"Khan","year":"2015","journal-title":"Atheroscler Suppl."},{"key":"B48","first-page":"494","article-title":"Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study","volume":"23","author":"Bengsch","year":"2005","journal-title":"Shock."},{"key":"B49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1525-1594.1998.06011.x","article-title":"HELP Apheresis in the treatment of sepsis","volume":"22","author":"Samtleben","year":"1998","journal-title":"Artif Organs"},{"key":"B50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1046\/j.1526-0968.2001.00350.x","article-title":"Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach","volume":"5","author":"Jaeger","year":"2001","journal-title":"Therap Apheres."},{"key":"B51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00059-003-2497-5","article-title":"Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?","volume":"28","author":"Jaeger","year":"2003","journal-title":"Herz"},{"key":"B52","doi-asserted-by":"publisher","first-page":"101507","DOI":"10.1016\/j.jbc.2021.101507","article-title":"The binding of heparin to spike glycoprotein inhibits SARS-CoV-02 infection by three mechanisms","volume":"298","author":"Paiardi","year":"2022","journal-title":"J Biol Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0021-9150(98)00055-0","article-title":"Improvement of coronary vasodilatation capacity through single LDL apheresis","volume":"139","author":"Mellwig","year":"1998","journal-title":"Atherosclerosis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1161\/01.STR.30.9.1802","article-title":"Increased cerebral CO2 reactivity after heparin-mediated extracorporeal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia","volume":"30","author":"Pfefferkorn","year":"1999","journal-title":"Stroke."},{"key":"B55","year":""},{"key":"B56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"BSR20210611","DOI":"10.1042\/BSR20210611","article-title":"SARS-CoV-2 spike protein S1 induces fibrin(ogen)resistent to fibrinolysis: implications for microclot formation in COVID-19","volume":"41","author":"Grobbelaar","year":"2021","journal-title":"Biosci Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-021-01359-7","article-title":"Persistent clotting protein pathology in long COVID\/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin","volume":"20","author":"Pretorius","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B59","first-page":"1216","article-title":": Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1","volume":"2","author":"Ferrara","year":"1993","journal-title":"Transplant Proc"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1084\/jem.189.3.599","article-title":"C-reactive protein: a physiological activator of interleukin-6 receptor shedding","volume":"189","author":"Jones","year":"1999","journal-title":"J Exp Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12916-015-0327-2","article-title":"Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective","volume":"13","author":"Fiusa","year":"2015","journal-title":"BMJ Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3389\/fmicb.2021.698169","article-title":"Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms","volume":"12","author":"Proal","year":"2021","journal-title":"Front Microbiol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"550","DOI":"10.12688\/f1000research.54306.1","article-title":"Toxin-like peptides in plasma, urine and faecal samples from COVID-19 patients","volume":"10","author":"Brogna","year":"2021","journal-title":"F1000Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1007\/s00705-018-3967-7","article-title":"Cholesterol is important for the entry process of porcine deltacoronavirus","volume":"163","author":"Jeon","year":"2018","journal-title":"Arch Virol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1007636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T01:27:47Z","timestamp":1665451667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1007636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":65,"alternative-id":["10.3389\/fcvm.2022.1007636"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1007636","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"article-number":"1007636"}}